Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
نویسندگان
چکیده
The human epidermal growth factor receptor 3 (HER3) has in recent years been recognized as a key node in the complex signaling network of many different cancers. It is implicated in de novo and acquired resistance against therapies targeting other growth factor receptors, e.g., EGFR, HER2, and it is a major activator of the PI3K/Akt signaling pathway. Consequently, HER3 has attracted substantial attention, and is today a key target for drugs in clinical development. Sophisticated protein engineering approaches have enabled the generation of a range of different affinity proteins targeting this receptor, including antibodies and alternative scaffolds that are either mono- or bispecific. Here, we describe HER3 and its role as a key tumor target, and give a comprehensive review of HER3-targeted proteins currently in development, including discussions on the opportunities and challenges of targeting this receptor.
منابع مشابه
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
The use of antibodies in therapy and diagnosis has undergone an unprecedented expansion during the past two decades. This is due in part to innovations in antibody engineering that now offer opportunities for the production of "second generation" antibodies with multiple specificities or altered valencies. The targeting of individual components of the human epidermal growth factor receptor (HER...
متن کاملProduction of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
Bispecific antibodies have emerged in recent years as a promising field of research for therapies in oncology, inflammable diseases, and infectious diseases. Their capability of dual target recognition allows for novel therapeutic hypothesis to be tested, where traditional mono-specific antibodies would lack the needed mode of target engagement. Among extremely diverse architectures of bispecif...
متن کاملA Comparative Investigation of the Bispecific Antibody: Expression in Expi293F Cells and E.Coli
Aims: Bispecific antibodies are capable of targeting two cell surface markers simultaneously. Blinatumomab an anti-CD3/CD19 Bispecific T cell engager antibody (BiTE) is approved for clinical application by FDA. This BiTE effectively targets malignant cells in ALL (Acute Lymphoblastic Leukemia) patients. For production of large quantities of such antibodies in industrial settings choice of host ...
متن کاملQuantification of cell surface proteins with bispecific antibodies
Flow cytometry is an established method for fast and accurate quantitation of cellular protein levels and requires fluorescently labeled antibodies as well as calibration standards. A critical step for quantitation remains the production of suitable detection antibodies with a precisely defined ratio of antigen-binding sites to fluorophores. Problems often arise as a consequence of inefficient ...
متن کاملDevelopment and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested...
متن کامل